Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (July 2021)
23 slides from Little Green Pharma's investor presentation, Jul 1, 2021
Slide 1: Investor Presentation
For personal use only ASX:LGP Investor Presentation 1 JULY 2021
Slide 2: Disclaimer
Disclaimer For personal use only Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 This document does not constitute financial product advice or take into account your 215) (“LGP”) and its activities current as at the da
Slide 3: Corporate Overview
Corporate Overview For personal use only Capital Structure Register Breakdown4 Current Share Price1 $0.88 Institutional Shares Outstanding2,3 232,607,948 36% Options and Performance Rights on Issue 12,008,746 Others Market Capitalisation (undiluted)1,3 ~$204.7 million 52% Cash Reserves (31 Mar 2021,
Slide 4: Who we are
Who we are For personal use only Little Green Pharma (ASX:LGP) • Vertically integrated medicinal cannabis company in Australia and Denmark • Focused solely on pharmaceutical grade cannabis to treat medical conditions • Australia’s first producer and exporter of cannabis medicines • ~12,000 patients
Slide 5: Vision and purpose
For personal use only We are passionate about transforming lives. Our vision is to reimagine cannabis medicines and do extraordinary things for our patients. Our purpose is to solve real patient problems. It’s at the heart of everything we do and defines our culture. We are proud of what we’ve done
Slide 6: Our ESG commitment
Our ESG commitment LGP solves societal and environmental challenges through core business activities For personal use only SIX DIMENSIONS OF IMPACT Economic vitality H Access and inclusion M Environmental sustainability L 0 Societal enablement Lifetime well-being Ethical capacity 6 Source: Model bas
Slide 7: For personal use only
For personal use only
Slide 8: Our Business Model Captures Value
Our Business Model Captures Value LGP operates across the entire medicinal cannabis supply chain For personal use only Cultivation & Manufacturing Product Patient Access Sales & Production Innovation & Education Distribution EU GACP cultivation facility in EU-recognised GMP R&D pipeline includes thr
Slide 9: Growth Strategy
Growth Strategy Little Green Pharma has a track record of sales growth with a clear pathway to increasing margins and driving significant revenue growth in Australia and offshore markets For personal use only 1 Patient acquisition 2 3 Product and drug Clear pathway to in Australia international deli
Slide 10: Track Record of Patient Access
Track Record of Patient Access Strong growth in sales and patients using LGP products in Australia For personal use only TOTAL REVENUE AUSTRALIAN REVENUE $2.46m $2.45m 31 DEC 20 $1.81m $2.3m 31 MAR 21 31 DEC 20 31 MAR 21 UNITS SOLD TOTAL PATIENTS CASH AT BANK AUSTRALIA 11,900 $28.5m 54,700 9,500 37,
Slide 11: The QUEST Initiative
For personal use only The QUEST Initiative aims to be one of the world’s largest longitudinal studies investigating the quality of life and health economics of medicinal cannabis on patients with chronic disease The QUEST Difference QUEST has recruited 805 patients to date and involves 94 doctors ac
Slide 12: Clear Pathway to International Sales
Clear Pathway to International Sales For personal use only Medezin Sp. z o.o., a subsidiary of Pelion SA, appointed as exclusive distributor in Poland - Pelion SA is the largest operator in the Polish and Lithuanian healthcare sector Poland Medezin targets to sell Products equivalent to ≥20% of
Slide 13: Total Addressable Market
Total Addressable Market LGP’s total addressable market is estimated at ~$24bn1 at maturity For personal use only • The global medicinal cannabis is experiencing dramatic growth and LGP is one of a few companies world-wide with the capability to deliver into these new and emerging markets • The foll
Slide 14: Product Innovation
Product Innovation Solving real patient problems For personal use only ARISE The Company has now successfully applied medicinal cannabis Technology to its licensed, patented ARISE delivery technology Currently undertaking yield optimisation activities Plans to progress to: – upscaling and pre-
Slide 15: R&D Pipeline
R&D Pipeline For personal use only INNOVATE DEVELOP LAUNCH REGISTRATION • Identify key unmet patient • Patient focused drug design • Rapid path to market access • Market Authorisation needs • Launch new medicine in Australia (TGA, EMA, FDA) • Optimisation (SAS B) & global markets • Sponsor the QUEST
Slide 16: Cultivation & Manufacturing Capability
Cultivation & Manufacturing Capability For personal use only
Slide 17: LGP Australia
LGP Australia TGA-GMP manufacturing For personal use only facility licensed to produce flower, extracts (oils), tinctures and APIs Additional high-volume manufacturing and R&D capability with exclusive third party GMP licensed partner1 Indoor GACP cultivation facility capacity ~3 tonnes p.a. biomass
Slide 18: LGP Denmark
LGP Denmark For personal use only World class cannabis cultivation and manufacturing facility GACP cultivation and EU- recognised GMP manufacturing Exported to Australia, Germany and Czech Republic Production capacity of >20 tonnes p.a. biomass (~12 tonnes p.a. of dried cannabis flower) 21,500
Slide 19: LGP Positioning
LGP Positioning LGP is uniquely positioned to supply pharmaceutical-grade cannabis medicines across the globe For personal use only LGP’s cultivation capacity is >23 tonnes p.a. of cannabis biomass ensuring self sufficiency and long-term security of supply Biomass capacity This capacity positions th
Slide 20: For personal use only
For personal use only
Slide 21: News Flow – Making Solid Progress
News Flow – Making Solid Progress Significant commercial progress as LGP executes growth strategy For personal use only Commencement of first ethics approved large scale study Delivery of first flower products to Germany and oil medicines to New Zealand Delivery of first shipment to French trial pat
Slide 22: Why LGP?
Why LGP? Demonstrated lean business model For personal use only Market opportunity and pathway to capture market share Confidence in LGP by overseas partners Capacity to deliver (vertically integrated) Track record of execution 22
Slide 23: Connect
Connect For personal use only PO Box 690, West Perth Western AUSTRALIA 6872 P: +61 8 6280 0050 E: info@littlegreenpharma.com.au W: littlegreenpharma.com facebook.com/littlegreenpharma linkedin.com/company/little-green-pharma
Little Green Pharma — Investor Presentation (July 2021) on 6ix